Cover Image

Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution

High-dose (HD) chemotherapy followed by autologous blood stem-cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM) patients. However, the collection of sufficient peripheral blood stem cell (PBSC) grafts can be challenging, and the question arises whether reinfusion of low...

Full description

Saved in:
Bibliographic Details
Main Authors: Sauer, Sandra (Author) , Pavel, Petra (Author) , Schmitt, Anita (Author) , Cremer, Martin (Author) , Kriegsmann, Mark (Author) , Bruckner, Thomas (Author) , Jordan, Karin (Author) , Wuchter, Patrick (Author) , Müller-Tidow, Carsten (Author) , Kriegsmann, Katharina (Author)
Format: Article (Journal)
Language:English
Published: 25 April 2020
In: BMC cancer
Year: 2020, Volume: 20
ISSN:1471-2407
DOI:10.1186/s12885-020-06873-7
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-06873-7
Get full text
Author Notes:Sandra Sauer, Petra Pavel, Anita Schmitt, Martin Cremer, Mark Kriegsmann, Thomas Bruckner, Karin Jordan, Patrick Wuchter, Carsten Müller-Tidow and Katharina Kriegsmann
Description
Summary:High-dose (HD) chemotherapy followed by autologous blood stem-cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM) patients. However, the collection of sufficient peripheral blood stem cell (PBSC) grafts can be challenging, and the question arises whether reinfusion of low-dose grafts will lead to a hematopoietic recovery.
Item Description:Gesehen am 28.05.2020
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-020-06873-7

Similar Items